Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART)
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND HYPOTHESIS: It is well known that after prolonged abstinence, individuals who use their drug of choice experience a powerful euphoria that often precipitates relapse. While a biological explanation for this conundrum has remained elusive, we hypothesize that this clinically observed "supersensitivity" might be tied to genetic dopaminergic polymorphisms. Another therapeutic conundrum relates to the paradoxical finding that the dopaminergic agonist bromocriptine induces stronger activation of brain reward circuitry in individuals who carry the DRD2 A1 allele compared with DRD2 A2 allele carriers. Because carriers of the A1 allele relative to the A2 allele of the DRD2 gene have significantly lower D2 receptor density, a reduced sensitivity to dopamine agonist activity would be expected in the former. Thus, it is perplexing that with low D2 density there is an increase in reward sensitivity with the dopamine D2 agonist bromocriptine. Moreover, under chronic or long-term therapy with D2 agonists, such as bromocriptine, it has been shown in vitro that there is a proliferation of D2 receptors. One explanation for this relates to the demonstration that the A1 allele of the DRD2 gene is associated with increased striatal activity of L-amino acid decarboxylase, the final step in the biosynthesis of dopamine. This appears to be a protective mechanism against low receptor density and would favor the utilization of an amino acid neurotransmitter precursor like L-tyrosine for preferential synthesis of dopamine. This seems to lead to receptor proliferation to normal levels and results in significantly better treatment compliance only in A1 carriers. PROPOSAL AND CONCLUSION: We propose that low D2 receptor density and polymorphisms of the D2 gene are associated with risk for relapse of substance abuse, including alcohol dependence, heroin craving, cocaine dependence, methamphetamine abuse, nicotine sensitization, and glucose craving. With this in mind, we suggest a putative physiological mechanism that may help to explain the enhanced sensitivity following intense acute dopaminergic D2 receptor activation: "denervation supersensitivity." Rats with unilateral depletions of neostriatal dopamine display increased sensitivity to dopamine agonists estimated to be 30 to 100 x in the 6-hydroxydopamine (6-OHDA) rotational model. Given that mild striatal dopamine D2 receptor proliferation occurs (20%-40%), it is difficult to explain the extent of behavioral supersensitivity by a simple increase in receptor density. Thus, the administration of dopamine D2 agonists would target D2 sensitization and attenuate relapse, especially in D2 receptor A1 allele carriers. This hypothesized mechanism is supported by clinical trials utilizing amino acid neurotransmitter precursors, enkephalinase, and catechol-O-methyltransferase (COMT) enzyme inhibition, which have resulted in attenuated relapse rates in reward deficiency syndrome (RDS) probands. If future translational research reveals that dopamine agonist therapy reduces relapse in RDS, it would support the proposed concept, which we term "deprivation-amplification relapse therapy" (DART). This term couples the mechanism for relapse, which is "deprivation-amplification," especially in DRD2 A1 allele carriers with natural D2 agonist therapy utilizing amino acid precursors and COMT and enkepalinase inhibition therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
The debate over dopamine’s role in reward: the case for incentive salience
Berridge, K. C. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0578-x · Cited by 2,347
Drinking to regulate positive and negative emotions: A motivational model of alcohol use
Cooper, M. L., Frone, M. R., Russell, M., & Mudar, P. (1995) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.69.5.990 · Cited by 1,975
Dalgleish, T. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1432 · Cited by 1,849
The neural basis of loss aversion in decision-making under risk
Tom, S. M., Fox, C. R., Trepel, C., & Poldrack, R. A. (2007) · Science · doi:10.1126/science.1134239 · Cited by 1,733
How does stress increase risk of drug abuse and relapse?
Sinha, R. (2001) · Psychopharmacology · doi:10.1007/s002130100917 · Cited by 1,505
Evidence for striatal dopamine release during a video game
Koepp, M. J., Gunn, R. N., Lawrence, A. D., Cunningham, V. J., Dagher, A., Jones, T., Brooks, D. J., Bench, C. J., & Grasby, P. M. (1998) · Nature · doi:10.1038/30498 · Cited by 1,279
Abercrombie, E. D., Keefe, K. A., DiFrischia, D. S., & Zigmond, M. J. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09224.x · Cited by 1,106
Allelic Association of Human Dopamine D2 Receptor Gene in Alcoholism
Blum, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440150063027 · Cited by 1,055
Self-citation
Cited by
Fingerprinting food: current technologies for the detection of food adulteration and contamination
Ellis, D. I., Brewster, V. L., Dunn, W. B., Allwood, J. W., Golovanov, A. P., & Goodacre, R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35138b · Cited by 440
Blum, K., Gardner, E., Oscar-Berman, M., & Gold, M. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212798919110 · Cited by 218
Self-citationBlum, K. (2013) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.1000139 · Cited by 73
Self-citationThe Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery
Blum, K., Thompson, B., Demotrovics, Z., Femino, J., Giordano, J., Oscar-Berman, M., Teitelbaum, S., Smith, D. E., Roy, A. K., Agan, G., et al. (2015) · Journal of Reward Deficiency Syndrome · doi:10.17756/jrds.2015-008 · Cited by 73
Self-citationBlum, K., Steinberg, B., Gondré-Lewis, M. C., Baron, D., Modestino, E. J., Badgaiyan, R. D., Downs, B. W., Bagchi, D., Brewer, R., McLaughlin, T., et al. (2021) · Psychology Research and Behavior Management · doi:10.2147/prbm.s292958 · Cited by 20
Self-citation
Metadata
- Authors
- Blum, K., Chen, T. J. H., Downs, B. W., Bowirrat, A., Waite, R. L., Braverman, E. R., Madigan, M., Oscar-Berman, M., DiNubile, N., Stice, E., Giordano, J., Morse, S., & Gold, M.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2009-11-01
- Volume
- 121
- Issue
- 6
- Pages
- 176-196
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2136812067
- Cited by
- 77
- References
- 29
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART). https://app.cochat.ai/papers/10.3810/pgm.2009.11.2087
- The paper
- Blum, K., Chen, T. J. H., Downs, B. W., Bowirrat, A., Waite, R. L., Braverman, E. R., Madigan, M., Oscar-Berman, M., DiNubile, N., Stice, E., Giordano, J., Morse, S., & Gold, M. (2009). Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART). Postgraduate Medicine. https://doi.org/10.3810/pgm.2009.11.2087
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.